Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence

American Journal on Addictions

Volumn 10, Issue 1, 2001, Pages 48-68

  Posternak, M A ^a   Mueller, T I ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; LORAZEPAM;

AGORAPHOBIA; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY NEUROSIS; ATAXIA; COMORBIDITY; DEPERSONALIZATION; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; MEDICAL INFORMATION; NEUROTOXICITY; NONHUMAN; PANIC; PARESTHESIA; PSYCHOMOTOR DISORDER; PSYCHOSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEIZURE; SUBSTANCE ABUSE; TINNITUS; VISUAL DISORDER;

ANIMALS; ANXIETY DISORDERS; BENZODIAZEPINES; HUMANS; PROGNOSIS; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 0035096365     PISSN: 10550496     EISSN: None     Source Type: Journal    
DOI: 10.1080/105504901750160484     Document Type: Review

References (197)

1. Cross-national study of the extent of anti-anxiety/sedative drug use
2. Treating anxiety while minimizing abuse and dependence
3. The treatment of anxiety in patients with alcoholism
4. Evaluation and treatment of anxiety symptoms and disorders in alcoholics
5. Treating anxiety in patients with alcoholism
6. Treating the anxious patient with an addiction
7. Panic, agoraphobia, and panic disorder with agoraphobia: Data from a multicenter anxiety disorders study
8. The natural history of anxiety disorders
9. Chronic PTSD in Vietnam combat veterans: Course of illness and substance abuse
10. Quality of life in panic disorder
11. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder
12. Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans
13. Predictors of early suicide: Identification and appropriate intervention
14. Excess mortality in panic disorder: A comparison with primary unipolar depression
15. Double-blind clinical assessment of alprazolam, a new benzodiazepine derivative, in the treatment of moderate to severe anxiety
16. Multicenter double-blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients
17. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder
18. Bromazepam and diazepam in generalized anxiety: A placebo-controlled study with measurement of drug plasma concentrations
19. A comparison of buspirone, diazepam, and placebo in patients with chronic anxiety states
20. Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms
21. Long-term diazepam therapy and clinical outcome
22. Long-term treatment of anxiety and risk of withdrawal: Prospective comparison of clorazepate and buspirone
23. Panic disorders: Current perspectives
24. Current concepts in psychiatry: Panic attacks and phobias
25. Practice guideline for the treatment of patients with panic disorder
26. Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone
27. Response of panic disorder to fixed doses of alprazolam or imipramine
28. Maintenance drug treatment of panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine
29. Diazepam and propranolol in panic disorder and agoraphobia
30. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks
31. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia
32. A fixed-dose study of alprazolam 2mg, alprazolam 6mg, and placebo in panic disorder
33. Plasma alprazolam concentrations: Relation to efficacy and side effects in the treatment of panic disorder
34. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder: 2.5 year naturalistic follow-up study
35. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: A controlled study in London and Toronto
36. Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia
37. Memory functions, alprazolam and exposure therapy: A controlled longitudinal study of agoraphobia with panic disorder
38. Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia
39. Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: Conclusions from combined treatment trials
40. Characteristic psychiatric symptomatology of post-traumatic stress disorder in veterans: A three year follow-up
41. Chronic combat-related PTSD and concurrent substance abuse: Implications for treatment of this frequent "dual diagnosis"
42. Toward rational pharmacotherapy for posttraumatic stress disorder: An interim report
43. Posttraumatic stress disorder: Characteristics and pharmacological response in the veteran population
44. Pharmacotherapy for PTSD
45. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment
46. Treatment of social phobia with benzodiazepines
47. Cognitive-behavioral and pharmacological treatments of social phobia: A controlled study
48. Treatment of social phobia with clonazepam and placebo: A controlled study
49. Long-term treatment of social phobia with clonazepam
50. Desensitization and flooding (implosion) in treatment of phobias
51. Enhanced relief of phobias by flooding during waning diazepam effect
52. Alprazolam in the treatment of obsessive symptoms
53. Alprazolam in the treatment of compulsive symptoms
54. Alprazolam as treatment for a case of obsessive-compulsive disorder
55. Panic attacks and alcohol withdrawal: Can subjects differentiate the symptoms?
56. Pharmacological management of alcohol withdrawal: A meta-analysis and evidence-based practice guideline
57. Persistence of a "subacute withdrawal syndrome" following chronic ethanol intake
58. Studies on duration of a late recovery period after chronic abuse of ethanol. A cross-sectional study of biochemical and psychometric indicators
59. Should protracted withdrawal from drugs he included in DSM-IV?
60. Long-term recovery in alcoholics
61. Hyperventilation, anxiety, craving for alcohol: A subacute alcohol withdrawal syndrome
62. The relationship between craving, anxiety, and other symptoms in opioid withdrawal
63. Stress, vulnerability, and adult alcohol relapse
64. Efficacy of antianxiety drug therapy in alcohol post-intoxication symptoms. A double-blind study of chlorprothixen, oxazepam and placebo
65. Pilot open-label study of alprazolam in anxious alcoholic out-patients
66. Clinical symptomatology and computer analyzed EEG before, during and after anxiolytic therapy of alcohol withdrawal patients
67. Chlordiazepoxide: Long-term use in alcoholism
68. The use of tranquilizers in the treatment of mixed drug abuse
69. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the epidemiologic catchment area (ECA) study
70. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
71. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey
72. Posttraumatic stress disorder among substance users from the general population
73. Post-traumatic stress disorder in the general population: Findings of the epidemiologic catchment area survey
74. Traumatic events and posttraumatic stress disorder in an urban population of young adults
75. Social phobia: Comorbidity and morbidity in an epidemiologic sample
76. Alcoholism, anxiety disorders, and agoraphobia
77. Prevalence of anxiety disorders among alcoholics
78. Anxiety disorders and alcoholism: A study with inpatient alcoholics
79. The prevalence of psychiatric disorders in patients with alcohol and other drug problems
80. Psychopathology in hospitalized alcoholics
81. Prevalence, onset, and clinical recognition of panic states in hospitalized male alcoholics
82. Co-morbidity of lifetime psychiatric disorder among male alcoholic patients
83. Panic disorder and depression in female alcoholics
84. Alcohol dependence and phobic anxiety states, II. A retrospective study
85. Clinical phobias and avoidant personality disorder among alcoholics admitted to an alcoholism rehabilitation setting
86. Prevalence of additional psychiatric syndromes among male alcoholics
87. Combat-related posttraumatic stress disorder and severity of substance abuse in Vietnam veterans
88. Incest as a treatment issue for alcoholic women
89. The relation between alcohol problems and the anxiety disorders
90. Alcohol dependence and anxiety disorders: What is the relationship?
91. The association of alcoholism and anxiety
92. Alcoholism and panic disorder: Is the comorbidity more than coincidence?
93. Substance abuse and panic-related anxiety: A critical review
94. Minor tranquilizers and road accidents
95. Psychotropic drug use and the risk of hip fracture
96. Aggressive dyscontrol in patients treated with benzodiazepines
97. Chronic use of benzodiazepines and psychomotor and cognitive test performance
98. Enlargement of cerebrospinal fluid spaces in long-term benzodiazepine abusers
99. A 4-6 year follow-up of 50 patients with primary dependence on sedative and hypnotic drugs
100. Mortality of patients dependent on benzodiazepines
101. Current status of benzodiazepines (second of two parts)
102. Long-term therapeutic use of benzodiazepines, I. Effects of abrupt discontinuation
103. Long-term therapeutic use of benzodiazepines, II. Effects of gradual taper
104. Withdrawal reaction after long-term therapeutic use of benzodiazepines
105. Discontinuation of alprazolam treatment in panic patients
106. Lorazepam withdrawal seizures
107. Benzodiazepine abuse and dependence in psychiatric inpatients
108. Benzodiazepines and withdrawal psychosis. Report of three cases
109. Protracted withdrawal syndromes from benzodiazepines
110. Benzodiazepine dependence and withdrawal in elderly patients
111. Maintenance drug treatment for panic disorder, II. Short- and long-term outcome after drug taper
112. Prevalence of benzodiazepine abuse and dependence in psychiatric in-patients with different nosology: An assessment of hospital-based drug surveillance data
113. Sedative/tranquilizer use and abuse in alcoholics currently in outpatient treatment: Incidence, pattern, and preference
114. Objective determination of benzodiazepine use and abuse in alcoholics
115. Benefits versus risks of benzodiazepines
116. Dependence liability of several sedative-hypnotic agents evaluated in monkeys
117. Self-injection of barbiturates and benzodiazepines in baboons
118. Schedule-induced chlordiazepoxide intake: Differential effect of cocaine and ethanol histories
119. Reinforcing properties of diazepam under several condition in the rhesus monkey
120. Social behavior, dominance, and social deprivation of rats determine drug choice
121. Oral self-administration of triazolam, diazepam, and ethanol in the baboon: Drug reinforcement and benzodiazepine physiological dependence
122. Drug preference and mood in humans: Diazepam
123. Lack of preference for flurazepam in normal volunteers
124. Lack of preference for diazepam in anxious volunteers
125. Preference for diazepam in anxious adults
126. Benzodiazepines: Use, abuse, and consequences
127. Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men
128. Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: Subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone
129. Reinforcing and subjective effects of diazepam in nondrug-abusing volunteers
130. Preference for diazepam, but not buspirone, in moderate drinkers
131. Parental alcoholism as a risk factor in benzodiazepine abuse: A pilot study
132. Response to diazepam in sons of alcoholics
133. Diazepam preference in males with and without an alcoholic first-degree relative
134. Subjective feelings and changes in body sway following diazepam in sons of alcoholics and control subjects
135. Social effects of diazepam use: A longitudinal field study
136. Correlates of compliance with psychoactive prescriptions
137. Long-term benzodiazepine users 3 years after participation in a discontinuation program
138. Characteristics of long-term alprazolam users in the community
139. Safety and efficacy of long-term diazepam therapy
140. Patterns of benzodiazepine use in Great Britain as measured by a general population survey
141. Characteristics of long term benzodiazepine users in general practice
142. Clinical aspects of chronic use of alprazolam and lorazepam
143. Epidemiology of benzodiazepine dependence
144. Drug dependence in patients in psychiatric hospitals in Switzerland: A survey conducted in nine psychiatric hospitals from 1983-1986
145. Benzodiazepine use and abuse by patients at outpatient clinics
146. Prevalence of misuse of prescribed benzodiazepines in patients with primary anxiety disorder or major depression
147. Drug deprivation and reinforcement by diazepam in a dependent population
148. Differential craving between recovering abstinent alcoholic-dependent subjects and therapeutic users of benzodiazepines
149. Multiple drug use and psychiatric comorbidity in patients admitted to the hospital with severe benzodiazepine dependence
150. Types of benzodiazepines abused by chemically dependent inpatients
151. Dimensions of multiple drug use and a typology of drug users
152. Diazepam use among methadone maintenance patients: Patterns and dosages
153. Alprazolam abuse during methadone maintenance therapy
154. Benzodiazepine and sedative use/abuse by methadone maintenance clients
155. The use of benzodiazepines among drug addicts
156. Alcoholism and drug abuse: Sociodemographic and toxicologic data
157. Drug preferences of alcoholic polydrug abusers with and without panic
158. "Mixed" (drug abusing) and "pure" alcoholics: A socio-medical comparison
159. Benzodiazepine use and anxiolytic abuse and dependence in treated alcoholics
160. Multiple substance abuse by alcoholics
161. Benzodiazepine use in anxiety disordered patients with and without a history of alcoholism
162. Non-benzodiazepine pharmacotherapy of anxiety and panic in substance abusing patients
163. The biological basis of benzodiazepine dependence
164. Length of anxiolytic treatment and benzodiazepine withdrawal symptoms: A double-blind study with clotiazepam
165. Withdrawal symptoms after 6 weeks treatment with diazepam
166. Development of long term use of psychotropic drugs by general practice patients
167. The long-term use of psychotropic drugs: A follow-up study in Italian general practice
168. Changing patterns of psychotropic drug use in the elderly: A five-year update
169. Longitudinal study on the consumption of analgesics, tranquilizers and hypnotics by healthy Swiss men over a 13-year period (1972-1985)
170. Controlled discontinuation of benzodiazepine treatment for patients with Panic disorder
171. One-year follow-up of anxious patients treated with diazepam
172. A follow-up study of patients treated for benzodiazepine dependence
173. Inpatient withdrawal from long-term benzodiazepine use
174. Benzodiazepine withdrawal: Outcome in 50 patients
175. Five year outcome in patients withdrawn from long term treatment with diazepam
176. Factors predicting long-term outcome after chronic benzodiazepine therapy
177. Patients, prescribing and benzodiazepines
178. Investigation of benzodiazepine-consumers concerning intake-habits, signs of abuse or dependence, and information about the drug
179. Patients' attitudes to benzodiazepine dependence
180. Personality test scores as predictors of alcoholism almost a decade later
181. Psychometric test changes following alcohol inpatient treatment and their relationships to posttreatment drinking behaviors
182. The concurrent use of alcohol, cigarettes and caffeine in British benzodiazepine users as measured by a general population survey
183. Tranquilizer use in middle-aged British men
184. Risk factors in the use of benzodiazepines
185. Minor tranquilizers: Clinical correlates of use in an urban population
186. The self-medication hypothesis of substance use disorders: A reconsideration and recent applications
187. Chlordiazepoxide in the treatment of alcoholics
188. Notes on the use of "librium" in the treatment of alcoholism
189. Drug maintenance in the outpatient treatment of chronic alcoholism
190. Prevalence and correlates of the long-term regular use of anxiolytics
191. Predicting response to alcohol and drug abuse treatments
192. Female alcoholics, I. Alcohol dependence and problems associated with prescribed psychotropic drug use
193. Prescribing for alcoholics: A survey of drugs taken prior to admission to an alcoholism unit
194. Effect of the requirement for triplicate prescriptions for benzodiazepines in New York State
195. Dr. Ciraulo and associates reply